Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
A new device made up of magnetic titanium beads may help certain patients who have problems controlling their bowels, a condition called fecal incontinence. The Fenix® Continence Restoration System mimics the function of the anal sphincter. It is the newest treatment option available to certain patients who have fecal incontinence caused by childbirth complications, trauma, prior surgeries, anal sex or another cause of muscle and nerve damage. Read more.
Source: Cleveland Clinic, March 9, 2017
Urinary incontinence is any involuntary urine leakage. It is a condition that can be more or less severe and it affects one in three women of all ages, which is more than 56 million people in Europe and more than 350 million people in the world. It is not a normal part of ageing and has a negative impact on the quality of life of the women who suffer from it. The main risk factors for urinary incontinence are pregnancy and childbirth, overweight and obesity, and high-impact sports. There are several treatments to improve or cure its symptoms, depending on the type of incontinence, and it can also be prevented by taking measures before it appears. One approach that has proven effective in preventing and treating stress urinary incontinence is pelvic floor muscle training. It consists of a programme of contraction and relaxation exercises for the muscles that form the base of the pelvis. If the treatment is followed and performed correctly with the supervision of a therapist, the rate of cure/improvement may reach 70% .Read more.
Source: News-Medical.net, March 9, 2017
The U.S. Food and Drug Administration today approved Noctiva (desmopressin acetate) nasal spray for adults who awaken at least two times per night to urinate due to a condition known as nocturnal polyuria (overproduction of urine during the night). Noctiva is the first FDA-approved treatment for this condition. “Today’s approval provides adults who overproduce urine at night with the first FDA-approved therapeutic option to help reduce the number of times a night they wake up to urinate,” said Hylton V. Joffe, M.D., M.M.Sc., director of the Division of Bone, Reproductive, and Urologic Products in the FDA’s Center for Drug Evaluation and Research. “It is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their health care provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them.” Read more.
Source: US FDA, March 3, 2017
The HARTMANN GROUP, a leading international supplier of medical and hygiene products, announced today it plans to acquire Procter & Gamble’s Lindor — one of the most well-known adult incontinence brands in the Spain and Portugal professional channel. The transaction seeks to take place by end of second quarter of fiscal year 2017 and is subject to approval by local antitrust authorities. As part of the agreement, HARTMANN is slated to obtain all P&G assets associated with the Lindor product portfolio (Lindor, Salvacamas, Lindor Care, Lindor Pants), Intellectual Property, contracts with employees, as well as a 25,000-square metre manufacturing facility in Montornés, Spain. Read more.
Source: Yahoo Finance, March 2, 2017
Solace Therapeutics, Inc., today announced that data from a multicenter 221 patient randomized controlled trial has met study endpoints with statistical significance. Dr. Eric Rovner will be presenting a poster of the results from the SUCCESS Clinical Trial at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) meeting in Scottsdale, Arizona on Thursday, March, 2nd. This is the Company’s third randomized controlled trial to evaluate the safety and efficacy of the Vesair Bladder Control System; a novel, office-based, reversible treatment designed to reduce or eliminate urine leakage in female patients with Stress Urinary Incontinence (SUI). Read more.
Source: Business Wire, March 1, 2017
Source: Nursing Times, March 1, 2017
Physical activity improves health and may delay the onset of chronic diseases. For women in particular, the rate of some chronic diseases accelerates at middle age around the time of menopause; therefore it is important to identify the determinants of health-enhancing physical activity during midlife in this population. The main aim of this study was to characterize the level of physical activity and to examine the association between different female reproductive factors and objectively-measured physical activity in middle-aged women. The reproductive factors included cumulative reproductive history index, and perceived menopausal and pelvic floor dysfunction symptoms. Read more.
Source: MedicalResearch.com, Feburary 28, 2017